-+ 0.00%
-+ 0.00%
-+ 0.00%
FDA Approves Regeneron's Livsayis for Generalized Myasthenia Gravis
Share
Listen to the news
FDA Approves Regeneron's Livsayis for Generalized Myasthenia Gravis
  • FDA approved Regeneron's Livsayis (cemdisiran) for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.
  • Livsayis is the first approved siRNA therapy for the disease, with subcutaneous dosing four times a year.
  • The treatment carries a boxed warning for serious meningococcal infections.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611181803PRIMZONEFULLFEED9880916) on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending